<DOC>
	<DOCNO>NCT00965432</DOCNO>
	<brief_summary>The objective study determine safety tolerability single oral dos STX107 determine basic pharmacokinetic ( PK ) parameter follow single oral dos STX107 administer via oral suspension</brief_summary>
	<brief_title>A Single-Dose Study Normal Volunteers Assess Safety , Tolerability Pharmacokinetics STX107</brief_title>
	<detailed_description />
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Normal , healthy male 1850 year old , inclusive . Able comprehend willing sign Informed Consent Form ( ICF ) . Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>